Sara Secall

Sara joined Inveready in 2013 and is responsible for building the Biotech Portfolio. While at Inveready she has led transactions such as AVX Pharma and Edesa Biotech (both exited) and sits at the board of companies such as Oxolife, Aptatargtets and Oncostellae. Sara has an extensive international career in technology investing.

Prior to joining Inveready, as Director of Spin Outs for the University of Barcelona, she was involved in starting and financing over 25 technology start ups and she negotiated numerous technology licenses, mainly in the biotechnology sector. She started her career as an investor at Chevron Technology Ventures, Chevron’s corporate Venture Capital group based in California with USD 210 MM under management.

She has worked extensively in the USA, Latin America and Europe.

Sara holds a BS in Chemistry from Universitat de Barcelona, MSc from Indiana University and an MBA from the London Business School.